PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
ANNÉE
2022
AUTEURS
Tougeron D, Dahan L, El Hajbi F, KLe Malico K, Evesque L, Aparicio T, Bouche O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, bodere A, Phelip JM, Mabro M, Artru P, Louvet C
CONGRÈS/REVUE
ESMO
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES